New developments in psychopharmacology
of attention deficit hyperactivity disorder
by
Pliszka SR.
Division of Child and Adolescent Psychiatry,
Department of Psychiatry,
The University of Texas Health Science Center at San Antonio,
7703 Floyd Curl Drive MC 7792,
San Antonio, TX 78229-3900, USA.
pliszka@uthscsa.edu
Expert Opin Investig Drugs 2001 Oct;10(10):1797-807

ABSTRACT

Stimulants have been the mainstay of the psychopharmacological treatment of attention deficit hyperactivity disorder (ADHD) for over 60 years. In the last 5 years, there have been a number of important developments in terms of potential new treatments for ADHD. Since stimulants have such a short half-life, considerable research has focused on the development of new delivery systems that will allow once-a-day dosing. New formulations of both amphetamine (AMP) and methylphenidate (MPH) have appeared which differ in terms of their optical isomers from the commonly used compounds. A wide variety of compounds are currently in development as therapeutic agents for ADHD. Some, like the stimulants, primarily impact the noradrenergic and dopaminergic neurotransmitter systems, while others have novel effects on the cholinergic, histaminergic and peptidergic systems. Advances in the pharmacogenetics of ADHD may lead to the development of yet more compounds in the near future.

Ice
OROS
History
Serotonin
Dopamine
The Ritalin Kid
VTA/glutamate
Self-medication
Worms on speed
Methylphenidate
Adderall and ADHD
Genetics and AD/HD
AD/HD: non-psychostimulants
Tomoxetine/atomoxetine (Strattera)
Amphetamine and Ritalin overprescription?
Food and drugs: Adderall v. Concerta for ADHD kids

Refs
and further reading

HOME
HedWeb
Nootropics
cocaine.wiki
Cannabis.net
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhappiness?
Utopian Surgery?
The Good Drug Guide
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World